HTL

Hamilton Thorne to Announce Q1 2024 Financial Results and Hold Conference Call on May 14, 2024

Retrieved on: 
Lunedì, Maggio 6, 2024
HTL, ART, Software, TSX, EDT, Conference, Research

and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three months ended March 31, 2024 before market open on Tuesday, May 14, 2024.

Key Points: 
  • and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three months ended March 31, 2024 before market open on Tuesday, May 14, 2024.
  • The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.ltd and on www.sedar.com .
  • The Company will follow with a conference call on the same day at 9:00 a.m. EDT to review highlights of the results.
  • All interested parties are welcome to join the conference call by dialing toll free 1-833-366-1126 in North America, or 1-412-317-0703 from other locations, and requesting the “Hamilton Thorne Conference Call.” The Company’s updated investor presentation and a recording of the call will be available on Hamilton Thorne’s website shortly after the call.

HTL Biotechnology, market leader in biopolymers, acquires the Modern Meadow's human recombinant collagen platform for beauty and biomedical applications

Retrieved on: 
Lunedì, Maggio 6, 2024
Collagen, Hyaluronic acid, Acceleration, Rheumatology, Biopolymer, HTL, A-DNA, Biotechnology, Acquisition, Modern Meadow, Beauty, GMP, Ophthalmology, Fine chemical

Notably, this acquisition includes Modern Meadow's platform of recombinant proteins, with the most advanced product being human recombinant collagen type III (rhCOL3).

Key Points: 
  • Notably, this acquisition includes Modern Meadow's platform of recombinant proteins, with the most advanced product being human recombinant collagen type III (rhCOL3).
  • HTL Biotechnology makes a notable entry into recombinant human collagen for cosmetic and medical uses, addressing not only identified Vegan ethical commitments needs but also unique and differentiating properties.
  • In a nascent market with high demand set to surpass the billion-dollar mark soon, this recombinant human collagen holds significant promise.
  • I am delighted to welcome, on behalf of HTL Biotechnology, the beauty and biomedical teams from Modern Meadow."

HTL Biotechnology, market leader in biopolymers, acquires the Modern Meadow's human recombinant collagen platform for beauty and biomedical applications

Retrieved on: 
Lunedì, Maggio 6, 2024
Collagen, Hyaluronic acid, Acceleration, Rheumatology, Biopolymer, HTL, A-DNA, Biotechnology, Acquisition, Modern Meadow, Beauty, GMP, Ophthalmology, Fine chemical

Notably, this acquisition includes Modern Meadow's platform of recombinant proteins, with the most advanced product being human recombinant collagen type III (rhCOL3).

Key Points: 
  • Notably, this acquisition includes Modern Meadow's platform of recombinant proteins, with the most advanced product being human recombinant collagen type III (rhCOL3).
  • HTL Biotechnology makes a notable entry into recombinant human collagen for cosmetic and medical uses, addressing not only identified Vegan ethical commitments needs but also unique and differentiating properties.
  • In a nascent market with high demand set to surpass the billion-dollar mark soon, this recombinant human collagen holds significant promise.
  • I am delighted to welcome, on behalf of HTL Biotechnology, the beauty and biomedical teams from Modern Meadow."

Hamilton Thorne Ltd. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Mercoledì, Aprile 10, 2024
ART, OTC Markets Group, HTL, Metro Toronto Convention Centre, Software, Conference, TSX, Research

Beverly, Massachusetts--(Newsfile Corp. - April 10, 2024) - Hamilton Thorne Ltd. (TSX: HTL) (OTC Pink: HTLZF), Hamilton Thorne Ltd. a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets., will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

Key Points: 
  • Beverly, Massachusetts--(Newsfile Corp. - April 10, 2024) - Hamilton Thorne Ltd. (TSX: HTL) (OTC Pink: HTLZF), Hamilton Thorne Ltd. a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets., will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 16 and 17 at the Metro Toronto Convention Centre.

Hamilton Thorne to Announce Q4 and Full Year 2023 Financial Results and Hold Conference Call on March 27, 2024

Retrieved on: 
Giovedì, Marzo 21, 2024
ART, HTL, Conference, TSX, Research, EDT, Software, Cryptocurrency

and TORONTO, March 21, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three and twelve months ended December 31, 2023 before market open on Wednesday, March 27, 2024.

Key Points: 
  • and TORONTO, March 21, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today announced that it will release its financial results for the three and twelve months ended December 31, 2023 before market open on Wednesday, March 27, 2024.
  • The press release, with accompanying financial information, will be posted on the Company’s website at www.hamiltonthorne.ltd and on www.sedar.com .
  • The Company will follow with a conference call on the same day at 9:00 a.m. EDT to review highlights of the results.
  • All interested parties are welcome to join the conference call by dialing toll free 1-833-366-1126 in North America, or 1-412-317-0703 from other locations, and requesting the “Hamilton Thorne Conference Call.” The Company’s updated investor presentation and a recording of the call will be available on Hamilton Thorne’s website shortly after the call.

KBRA Assigns Preliminary Ratings to HTL 2024-T53

Retrieved on: 
Lunedì, Aprile 1, 2024
Professional Services, Finance, ADR, HTL, TTM, CMBS, KLTV, RevPAR, NCF, Engineering, KBRA, Telescopic sight

KBRA announces the assignment of preliminary ratings to six classes of HTL 2024-T53, a CMBS single-borrower securitization.

Key Points: 
  • KBRA announces the assignment of preliminary ratings to six classes of HTL 2024-T53, a CMBS single-borrower securitization.
  • The collateral for the transaction is a $631.5 million fixed rate, interest-only mortgage loan.
  • The loan will be secured by the borrowers’ fee simple interests in 53 hotels, all located in 14 states.
  • As of TTM 1/2024, the portfolio achieved weighed average occupancy, ADR and RevPAR penetration rates of 106.9%, 109.1% and 118.8%, respectively.

Hamilton Thorne Appoints Dr. Ekaterina (Kate) Torchilin as President and CEO

Retrieved on: 
Giovedì, Dicembre 21, 2023
Tufts University, Purification, Software, Biologicals, Research, Acquisition, Cell culture, Cell, Connected health, Vaccine, ART, MBA, Thermo Fisher Scientific, Doctor of Philosophy, Harvard Business School, Health, Biochemistry, Growth, TSX, Patient, HTL, Management

Dr. Torchilin is succeeding David Wolf, who is retiring as President and CEO.

Key Points: 
  • Dr. Torchilin is succeeding David Wolf, who is retiring as President and CEO.
  • Dr. Torchilin will also join the Hamilton Thorne Board of Directors upon assuming the CEO role.
  • Hamilton Thorne Chairman David Wolf said: “We are delighted to welcome Kate as our new Chief Executive at this exciting time in our Company’s development.
  • He will also continue to work actively to develop acquisition initiatives and strategic stakeholder and industry relationships.

Hamilton Thorne Reports Revenue for the Quarter and Nine Months Ended September 30, 2023

Retrieved on: 
Lunedì, Novembre 13, 2023
Sale, Acquisition, Research, ART, HTL, Needle, Trade Adjustment Assistance, IVF, Azerion Group N.V., Hand, Software, Growth, Assisted reproductive technology, TSX, Pharmaceutical industry, Video game

and TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the quarter and nine months ended September 30, 2023.

Key Points: 
  • and TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the quarter and nine months ended September 30, 2023.
  • David Wolf, President and Chief Executive Officer, of Hamilton Thorne Ltd. commented, “Sales grew 16% for the quarter while sales for the year were up 17%.
  • While some of this reduction is transient, with orders up for Q4, these trends have been impacting our business for some time; however, we expect we are likely reaching a bottom.
  • Constant currency sales as reported were up 12% for the quarter and 16% for the first nine months ended September 30, 2023.

Cerba HealthCare Changes Its Governance and Appoints Emmanuel Ligner Group Chief Executive Officer

Retrieved on: 
Giovedì, Novembre 9, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Otsuka Pharmaceutical, Abbott, Iveco, Exor, History, Leo Pharma, Pathology, Zodiac Aerospace, HTL, CGG, Development, Procter & Gamble, Commercialization, GE, Supervisory board, Procter, Senior advisor, ICON PLC, Stellantis, Pharmaceutical industry, Management, Allergan, Thales of Miletus

Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group.

Key Points: 
  • Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group.
  • Cerba HealthCare aims to remain at the forefront of medical innovation to help develop new treatments and improve patient health.
  • Emmanuel Ligner, Group Chief Executive Officer, said: « Cerba HealthCare is a leading company in the field of medical diagnostics as evidenced by the Group’s growth and the importance it has placed on innovation since its very inception.
  • »
    Jérôme Thill, Senior Advisor and former Chief Executive Officer of the Group, adds: « As I step down as Chief Executive Officer, I would like to thank all of Cerba HealthCare’s teams and partners.

The 11th Asia Pacific Financial Investment Association Summit to be Grandly Held in Sydney, Australia on the 16th of November, 2023

Retrieved on: 
Mercoledì, Novembre 8, 2023
Evolution, National Australia Bank, ESG, Financial services, HTL, Entrepreneurship, Investment, Application, Artificial intelligence, Development, German tourism industry, Challenge, Singapore Space and Technology Ltd, Marketing, Recovery, Hotel, Ministry of Villages, Development of Disadvantaged Regions, and Transmigration, W Hotels, High, Communication, Traditional investments, Alternative investment, Crown Hotel, Management, Renewable energy, Tourism, Bank

Sydney, Australia--(Newsfile Corp. - November 8, 2023) - On the 16th of November, 2023, the 11th Asia Pacific Financial Investment Association (APFIA) Summit, hosted by the Asia Pacific Financial Investment Association and proudly sponsored by Australia's High Titanium Resources and Technology Ltd (HTL), will be held as scheduled at W Hotel in Sydney.

Key Points: 
  • Sydney, Australia--(Newsfile Corp. - November 8, 2023) - On the 16th of November, 2023, the 11th Asia Pacific Financial Investment Association (APFIA) Summit, hosted by the Asia Pacific Financial Investment Association and proudly sponsored by Australia's High Titanium Resources and Technology Ltd (HTL), will be held as scheduled at W Hotel in Sydney.
  • On the 2nd December, 2021, the 9th Asia-Pacific Financial Summit was successfully held at the iconic Crown Hotel in Sydney.
  • The 11th APFIA Summit, as a reputable event in the global financial arena, carries immense significance for the economic growth of the Asia Pacific region.
  • Serving as a crucial platform for financial investment cooperation, this summit will also act as a bridge to the super financial investment market, facilitating cross-border opportunities, exploring fresh investment avenues, and beginning a new chapter in Asia Pacific finance.